The emerging class of GLP-1 receptor and GIP dual medications, such as tirzepatide, semaglutide, and the relatively introduced retatrutide, offer groundbreaking progress in metabolic management . Despite https://peptide-education523946.bloggadores.com/42451179/retatrutide-a-comparative-review